Immuron (IMRN) 6-K: IMM-529 IND approved by FDA, Ex. 99.1

Immuron Limited (IMRN) furnished a Form 6-K announcing it has attached an Australian Securities Exchange notice as Exhibit 99.1.

Rhea-AI Filing Summary

Immuron Limited (IMRN) furnished a Form 6-K announcing it has attached an Australian Securities Exchange notice as Exhibit 99.1. The exhibit is titled “IMM-529 IND approved by FDA”, indicating the company reported an FDA approval of an Investigational New Drug for IMM-529. The ASX announcement was published on November 5, 2025.

The report states it is being furnished, not filed, under the Exchange Act and will not be incorporated by reference into other filings except where expressly referenced.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immuron (IMRN) submit to the SEC?

A Form 6-K furnishing an Australian Securities Exchange announcement as an exhibit.

What is in Exhibit 99.1 of Immuron’s 6-K?

An announcement titled “IMM-529 IND approved by FDA”.

When was the related ASX announcement published?

On November 5, 2025.

Does the 6-K count as a filed document for incorporation by reference?

No. It is furnished, not filed, and not incorporated by reference unless expressly stated.

What does the exhibit title suggest about IMM-529?

It indicates an FDA approval of an Investigational New Drug for IMM-529, as per the exhibit title.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/05/2025 - 06:40 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2025

Commission File Number: 001-38104

IMMURON LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐      No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

IMMURON LIMITED

EXPLANATORY NOTE

Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on November 5, 2025 titled:

- IMM-529 IND approved by FDA

-

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		IMM-529 IND approved by FDA

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IMMURON LIMITED
Date: November 5, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3